| Dr Jeffrey Lawrence Bonacci, MD | |
|
315 E Warwick Dr, Ste 3, Alma, MI 48801-1083 | |
| (989) 463-6699 | |
| (989) 466-2574 |
| Full Name | Dr Jeffrey Lawrence Bonacci |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 20 Years |
| Location | 315 E Warwick Dr, Alma, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558575829 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 4301083704 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Midmichigan Medical Center-gratiot | Alma, MI | Hospital |
| Midmichigan Medical Center-clare | Clare, MI | Hospital |
| Midmichigan Medical Center-midland | Midland, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jeffrey Smith, Md Pc | 3870672843 | 6 |
News Archive
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment announced the launch of the JANUS® BioTx ProTM automated workstation for improved process development of protein therapeutics at the 12th Annual Protein Science Week (PepTalk), January 21-25 in Palm Springs, Florida at booth #312.
› Verified 5 days ago
| Entity Name | Jeffrey Smith, Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023196458 PECOS PAC ID: 3870672843 Enrollment ID: O20080501000304 |
News Archive
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment announced the launch of the JANUS® BioTx ProTM automated workstation for improved process development of protein therapeutics at the 12th Annual Protein Science Week (PepTalk), January 21-25 in Palm Springs, Florida at booth #312.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Lawrence Bonacci, MD 315 E Warwick Dr, Ste 3, Alma, MI 48801-1083 Ph: (989) 463-6699 | Dr Jeffrey Lawrence Bonacci, MD 315 E Warwick Dr, Ste 3, Alma, MI 48801-1083 Ph: (989) 463-6699 |
News Archive
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment announced the launch of the JANUS® BioTx ProTM automated workstation for improved process development of protein therapeutics at the 12th Annual Protein Science Week (PepTalk), January 21-25 in Palm Springs, Florida at booth #312.
› Verified 5 days ago
Dr. Ernest A Cudjoe, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 315 E Warwick Dr, # 3, Alma, MI 48801 Phone: 989-463-6699 Fax: 989-466-2574 | |
Peter J Bruno, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 245 E Warwick Dr, Alma, MI 48801 Phone: 989-463-5928 Fax: 989-463-5967 | |
Dr. Jeffrey F Smith, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 315 E Warwick Dr, Suite #3, Alma, MI 48801 Phone: 989-463-6699 Fax: 989-466-2574 | |
James D Pilkington, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 315 E Warwick Dr, Ste 3, Alma, MI 48801 Phone: 989-463-6699 Fax: 989-466-2574 |